Extending kidney donor criteria, including donation after circulatory death (DCD), has resulted in increased rates of delayed graft function (DGF) and primary nonfunction. Here, we used Nuclear Magnetic Resonance (NMR) spectroscopy to analyze the urinary metabolome of DCD transplant recipients at multiple time points (days 10, 42, 180, and 360 after transplantation). The aim was to identify markers that predict prolonged duration of functional DGF (fDGF). Forty-seven metabolites were quantified and their levels were evaluated in relation to fDGF. Samples obtained at day 10 had a different profile than samples obtained at the other time points. Furthermore, at day 10 there was a statistically significant increase in eight metabolites and a decrease in six metabolites in the group with fDGF (N = 53) vis-à-vis the group without fDGF (N = 22). In those with prolonged fDGF (≥21 days) (N = 17) urine lactate was significantly higher and pyroglutamate lower than in those with limited fDGF (<21 days) (N = 36). In order to further distinguish prolonged fDGF from limited fDGF, the ratios of all metabolites were analyzed. In a logistic regression analysis, the sum of branched-chain amino acids (BCAAs) over pyroglutamate and lactate over fumarate, predicted prolonged fDGF with an AUC of 0.85. In conclusion, kidney transplant recipients with fDGF can be identified based on their altered urinary metabolome.
period, DGF leads to prolonged hospitalization, more renal biopsies and an increased risk of acute rejection and graft loss. 4 However, the impact of DGF on long-term outcomes remains controversial. Some studies reported an increased risk of allograft failure, 4,5 whereas others did not find such a relationship. 6, 7 Therefore, the identification of biomarkers specific for proximal tubular epithelial cell injury would allow to monitor functional recovery and additional insults, such as acute rejection. This in turn would improve the daily clinical management of kidney transplant recipients.
To date, several proteins have been considered as potential markers to monitor DGF, including neutrophil gelatinase-associated lipocalin (NGAL), 8 kidney injury molecule-1 (KIM-1) and interleukin-18 (IL-18). 9, 10 In response to tubular injury, these proteins are upregulated and secreted in urine. Unfortunately, they were found to have low specificity for tubular epithelial cell injury. For example, NGAL and IL-18 are also produced by immune cells and increased urinary values were found in patients with urinary tract infections and sepsis. [11] [12] [13] As a result, studies have reported mixed levels of accuracy for the prediction of DGF with areas under the receiving operating curves (AUC-ROC) ranging from 0.60 to 0.90 for NGAL, 8 0.57 to 0.68 for KIM-1, 9,10 and 0.70 to 0.82 for IL-18. 9, 10 Due to these inconsistent results, in combination with a lack of clear cut-off values, translation of these biomarkers into daily clinical practice has not been achieved.
An alternative or complementary approach in the search for better proximal tubular epithelial cell markers could be analysis of smaller molecules, eg, the metabolic composition of urine using metabolomics. Metabolomics is a postgenomic discipline, studying the metabolites and their interactions. 14 Studies of the metabolome include the analysis of complex mixtures found in body fluids (eg, urine, blood, etc.), or tissues and cells, and are usually performed by Nuclear Magnetic Resonance (NMR) spectroscopy or mass spectrometry (MS), often coupled to chromatography. 14 NMR is not as sensitive as the MS-based methods but it has several advantages which are important for clinical studies, eg, it requires minimal sample preparation and provides excellent reproducibility. 15 Moreover, NMR allows the identification and quantification of a wide range of metabolites with a single measurement without extensive use of internal standards.
15,16
The potential of the metabolomics approach has already been demonstrated in nephrology and in particular in drug-induced nephrotoxicity, 17 diabetic nephropathy, 18 as well as acute kidney injury (AKI). [19] [20] [21] Metabolic changes in IRI have been investigated in studies with both human and murine models. [22] [23] [24] [25] [26] It was shown, that IRI resulted in early and sustained metabolic changes in urine, plasma, and kidney tissue. Several identified metabolites were the result of increased glycolysis and gluconeogenesis after ischemic injury, 22, 24 whereas others were attributed to oxidative stress. 23 Much less is known for metabolic changes longer after IRI, at the time of regeneration and repair. One study investigated metabolome alterations in urine 1 week after transplantation, 27 showing that several markers of medullary injury, tubule cell oxidative metabolism, and impaired tubular reabsorption or secretion could be detected. However, those metabolic changes were not related to DGF.
In the current study, we used proton ( The occurrence of DGF was defined according to the functional definition (fDGF). 6 Classically, DGF has been defined by the need for dialysis in the first week after renal transplantation. Definitions, however, differ between centers and individual patients are dialyzed for reasons other than impaired graft function. 30 Using daily serum creatinine levels, we classified transplant recipients with fDGF if, immediately after surgery, serum creatinine levels increased, remained unchanged, or decreased by less than 10% per day during three consecutive days with the second day as index on day 7 after surgery. 6, 31 A patient was defined having prolonged fDGF if the serum creatinine level increased, remained unchanged, or decreased by less than 10%
| MATERIAL S AND ME THODS

| Patients
per day during three consecutive days with the second day as index on postoperative day 21.
| Urine collection and NMR sample preparation
Spot urine samples were collected at day 10, 42, 180, and 360 posttransplantation following the same standard operating procedure (SOP) throughout the whole study. The sampling procedure included the collection of midstream urine in the morning after 8 hours fasting. Urines were immediately centrifuged for 10 minutes at 1000 × g, and split in aliquots of 1 mL which were stored TSP signal at 0.00 ppm. An additional set of 2D NMR spectra were also recorded on a small subset of samples and was used for the assignment of metabolites. All NMR instrumental, acquisition and processing parameters used in this study are described in detail in the supporting information. 
| Identification and quantification of metabolites
| Statistical analysis of NMR data
Preprocessing of NMR data prior to statistical analysis was performed with in house routines written in Matlab 2014a (The Mathworks, Inc., Natick, MA) and Python 2.7 (Python Software Foundation, https://www.python.org). Statistical analysis was done in R (http://www.r-project.org/, R versions 3.3.1 and 3.3.2).
All steps and the tools used for data processing and analysis are provided in the supporting information. The initial dataset consisted of 293 bins (variables) and 283 samples (observations) and was constructed using: (1) adaptive intelligent binning 34 of the spectral region from 0.5 to 9.5 ppm, (2) normalization with the Probabilistic Quotients Normalization method (PQN) 35 to correct for dilution differences from sample to sample, and (3) scaling to unit variance. Exploratory multivariate statistical analysis was performed using principal components analysis (PCA). Models comparing samples from the same time point (ie, with unique patient IDs) were subjected to a 7-fold cross validation scheme while those including multiple time points (ie, including data from the same patient more than once) were cross validated using the patient IDs as groups and leave one group out per round. of each metabolite, all data was scaled using the pooled standard deviation. All plots were made in R using the "ggplot2" and "dplyr" packages.
A variable selection for a classification model was performed using a two-step approach. At first, a subset of the variables (log-transformed relative concentrations) was selected using the Random Forest (RF) algorithm ("randomForest" R package), a method that combines the re-sampling of the data with a random feature selection. During the RF selection the out-of-bag error (OBB) was used for estimation of the generalization error.
The Gini-index (ie, the training error) and the Mean Square Error (MSE) were used for the variable selection. Subsequently, this selection was filtered for collinearity ("caret" R package) and the final model was built using a step function. The fitted model with the selected variables was further validated using a 5-fold crossvalidation (R packages "caret" and "boot"). In addition, the subset of the selected variables, were inputted in a KNN algorithm and their performance was tested after the cohort was randomly split in a training and a prediction set. For the KNN analysis the R packages "class" and "gmodels" were used.
| RE SULTS
| Baseline characteristics
Baseline characteristics are described in Table 1 . Two patients lost their graft due to thrombosis within the first week posttransplant, and were excluded from the current analysis. From the remaining cohort of 90 patients, in total 23 were classified as having no fDGF, 43
limited fDGF and 24 prolonged fDGF. Baseline characteristics were compared between patients with and without fDGF and between patients with limited and prolonged fDGF (Table 1) . DCD kidney transplant recipients with fDGF had on average longer cold ischemia time (P = .049). Compared to limited fDGF, patients with prolonged fDGF were older (P = .025), were more likely to have a male donor (P = .023) and had more mismatches for HLA class I antigens (P = .035) ( Table 1) The limited fDGF group of patients recovered on average on day 14 while the prolonged fDGF patients recovered on day 30.
As expected the former group had more urinary output on day 10 (P = .025) comparing to prolonged fDGF patients but this did not resulted in a difference in estimated glomerular function (eGFR) 36 on day 10 (P = .241). The AUCs on day-10 that guided CsA-dosing were 
| Overview of urinary profiles
Urine was collected at day 10, 42, 180, and 360 posttransplanta- 
| Targeted analysis of urine spectra
In order to further investigate the impact of fDGF on urinary profiles at day 10, a set of 47 metabolites was quantified. The complete list of the quantified compounds is shown in Figure 1 .
It has been shown that 167 ± 19 metabolites can be quantified in NMR spectra of urines from healthy individuals. 16 However, it is common in metabolomics studies based on NMR spectroscopy to report sets of 40 to 50 quantified compounds. 16 Here, following identification of the metabolites observed in our spectroscopic data and comparison with data deposited in the Human Urine
Metabolome Database, 16 we quantified and studied the levels Figure 2 ). Urine lactate concentration was increased while pyroglutamate was decreased in patients with prolonged fDGF compared to those with limited fDGF. In addition, the levels of formate, betaine and the branched chain amino acids (leucine, isoleucine, and valine) tended to be higher in patients with prolonged fDGF, while trigonelline, succinate, psedouridine, creatinine, dimethylamine (DMA), trimethylamine-N-oxide (TMAO), and fumarate, tended to be lower in these patients ( Figure 2 ). However, these differences were not statistically significant at P < .05 after correction for multiple testing. F I G U R E 1 Mean concentrations of urine metabolites (log 10 transformed) at day 10 of the patients without fDGF (no fDGF), with limited fDGF and with prolonged fDGF. Metabolites are ranked based on their levels in the no fDGF group. Horizontal lines represent the 1st and 3rd quartiles. Triangles indicate a significant (P < .05) difference of metabolite levels between the no fDGF and limited fDGF patients, while squares indicate a significant difference between no fDGF and prolonged fDGF patients. Asterisks indicate the metabolites the differ significantly after Kruskal-Wallis analysis of all three groups with *P < .05, **P < .01, and ***P < .001. fDGF, functional delayed graft function [Color figure can be viewed at wileyonlinelibrary.com] F I G U R E 2 Mean differences (in standard deviation units) of urine metabolites at day 10 between patients with and without fDGF (left) and between patients with limited and prolonged fDGF (right). Metabolites are ranked based on the values of the mean differences between patients with and without fDGF. Horizontal lines represent the 95% confidence intervals, and triangles and squares indicate the significant (P < .05) differences. The pooled standard deviation of the whole cohort was used for scaling. fDGF, functional delayed graft function [Color figure can be viewed at wileyonlinelibrary.com]
TA B L E 2 Number of patients and samples used in the study
| Association of prolonged fDGF with metabolic ratios
In order to address the clinically most relevant goal, that is the distinction between the limited and prolonged fDGF group, the ratios of metabolites were calculated. The metabolites that increased by at least 0.5 standard deviations were divided by those that decreased by at least 0.5 standard deviations. In total, 85 ratios were extracted and evaluated (supporting information Figure S2 , Table S2 ) and 33 ratios were found to differ significantly (P < .05) between the limited and the prolonged fDGF group (Figure 3 ).
Subsequently, we used this set of 33 metabolic measures as input in a two-step variable selection method in order to depict a minimal subset that provides the optimal discrimination of the prolonged fDGF. Following this filtering approach, we found that the combination of lactate/fumarate (P = .00405) and branched chain amino Supplementary Table S3 ). Furthermore, we applied the k-nearest F I G U R E 3 Mean differences (in standard deviation units) of the metabolite ratios at day 10 that differ significantly between patients with limited and prolonged fDGF. Horizontal lines represent the 95% confidence intervals. The pooled standard deviation of the whole cohort was used for scaling. fDGF, functional delayed graft function [Color figure can be viewed at wileyonlinelibrary. com]
neighbors (k-NN) algorithm, in order to get an additional assessment of the two selected ratios. The data set was randomly split into a training set (n = 50) and a prediction set (n = 25 and onwards, all metabolites included in the two ratios have similar median levels (supporting information Figure S3 ). These levels, as well as the calculated ratios lactate/fumarate and BCAAs/pyroglutamate, are in the same range as in the group of patients with no fDGF or limited fDGF at day 10. Therefore, the different levels of the two ratios as seen in urines on day 10, occur only for this time point and only for patients with prolonged fDGF.
| D ISCUSS I ON
This study assessed the urinary metabolic changes in a cohort of DCD kidney transplant recipients, to identify features associated with the presence and duration of functionally defined DGF. We used NMR in order to develop a robust, high-throughput and quantitative method for the profiling of urines. Complexity of the data was reduced in order to obtain a small set of metabolic features that can be characterized and quantified easily. We ultimately tested the performance of these features as measures to assess the duration of the fDGF after DCD kidney transplantation.
Multivariable analysis of the total urine metabolome demonstrated that urine samples obtained 10 days after transplantation had a different urinary profile compared with samples obtained at days 42, 180, and 365. In the samples taken at day 10, a set of 14 metabolites and 40 metabolic ratios differed significantly (P < .05) between patients without fDGF and with fDGF. In this latter group, two metabolites, lactate and pyroglutamate, as well as 33 metabolic ratios differed significantly between the patients with limited (<21 days) and with prolonged (≥ 21 days) fDGF. Ratios of lactate/ fumarate, and BCAAs/pyroglutamate were strong predictors of prolonged fDGF (AUC 0.85).
In kidney transplant recipients, few studies have investigated urinary metabolic profiles after transplantation. Two studies have compared urinary metabolic profiles 7 days after transplantation to those obtained after 3 and 12 months. 27, 29 In both studies, the profiles differed. In addition, one of these studies has shown that patients with immediate graft function had a different metabolic signature compared to those with delayed graft function. 29 It should be noted, that the number of patients with DGF was small (n = 8). Following a combined NMR and GC-MS method in 38 kidney transplant recipients, the main pathways affected 7 days after transplantation were the taurine/hypotaurine metabolism, the dimethylamine/methane metabolism, the citrate cycle, the inositol phosphate metabolism and the glycolytic pathway. 27 This however did not correlate with DGF status.
In another study with 15 transplant recipients by Calderisi et al., it was shown that the metabolic profiles within 2 weeks after transplantation were related to the stage of recovery. 37 In this study, lipoproteins, creatine, creatinine, and to a lesser extent mannitol, acetate, glucose, 2-aminobutyrate, valine, p-hydroxyhippurate, fumarate, 2-ethylacrylated, leucine, and lactate were found increased and levels of asparagine, dimethylglycine, 3-hydroxyisobutyrate, 3-hydroxyisovalerate, 2-hydroxyisobutyrate, and histidine were decreased. Differences in the urinary metabolome of patients with and without fDGF are to be expected considering the differences in urine output and in conventional parameters of renal function. The added value of this study is that 10 days after transplantation, we discovered urine markers which were significantly different in the patients who would have prolonged fDGF: lactate, pyroglutamate and a number of metabolic ratios. The concept of using ratios of metabolites is not new. Specific metabolic ratios are being used in large epidemiological studies, 39 while in genome-wide association studies, 40, 41 all ratios of metabolites pairs are evaluated in a hypothesisfree context and the biochemical connection of significant pairs with specific enzymes or pathways is attempted. In the present study, instead of using all possible combinations of metabolite pairs, we first calculated the mean differences of metabolites between limited and prolonged fDGF ( Figure 2 ) and subsequently, divided the values of metabolites that increased by at least 0.5 standard deviation by those that decreased by at least 0.5 standard deviation. Using this approach, we were able to (technically) increase the discriminatory power of the analysis, while still using actual urinary metabolic measures. Specifically, any BCAA alone (eg, valine, leucine, or isoleucine, see Figure 3 and Supplementary Table S2) The concentration of a biomarker in urine is determined by several factors, including filtration, proximal and/or distal reabsorption, secretion, and its release from injured cells ( Figure 5 ). After IRI, however, filtration and reabsorption capacity are more or less impaired, whereas the release from injured cells may be increased.
Looking at the characteristics of the metabolites included in the ratios, it is apparent that the majority of these metabolites are filtered was decreased, indicating a downregulation of this transporter. 43 Succinate and fumarate are intermediates of the Krebs cycle.
Succinate can regulate the blood pressure via the SUCNR1 receptor in the macula densa, 44 but it is also reabsorbed proximally by the SLC13A2 receptor. 45 Recently, it has been shown that mice and humans show conflicting results with regard to succinate accumulation in kidney tissue, with progressive succinate accumulation during ischemia in mice, and decreasing levels in human. 46 In accordance with decreased accumulation of succinate in tissue, we also found lower levels of urinary succinate in recipients with prolonged fDGF compared to those with limited fDGF. Betaine is a metabolite that protects the medulla from osmotic stress and in rats it was shown that reabsorption of betaine occurred both in the proximal and in the distal tubules. 47, 48 Lastly, the metabolites pyroglutamate and lactate are both reabsorbed by the same sodium-coupled receptor via SCL5A8, which is located predominantly in the S3 segment of mouse kidney. [49] [50] [51] Lactate, the end product of anaerobic glycolysis, is also synthesized by the kidney itself. 52 Previously, it was shown that there is a persistent high release of lactate in kidneys from deceased donors with DGF. 26 So, the metabolites associated with prolonged fDGF are handled by proximal tubular epithelial cells and therefore most likely to reflect tubular (dys)function ( Figure 5 ).
Notably, the levels of the ratios BCAAs/pyroglutamate and lactate/fumarate and each of the metabolites contributing to these ratios become similar in all patients at day 42 and the later time points.
On day 42, there is not any patient in the cohort with unresolved fDGF. Interestingly, the metabolic levels on day 42 are in the same range with the ones measured for both no fDGF and limited fDGF patients on day 10 (supporting information, Figure S3 ). This outcome clearly points to the influence of unresolved fDGF on the urinary levels of leucine, isoleucine, valine, lactate, fumarate, and pyroglutamate at the early phase after transplantation. Furthermore, it provides an additional evidence that the ratios BCAAs/pyroglutamate and lactate/fumarate could be used to specifically predict prolonged fDGF.
Although the findings of this study are consistent within the studied cohort, we are aware that a larger independent cohort of patients is necessary to validate the selected ratios.
Unfortunately, we were unable to find an independent cohort of DCD kidney transplant recipients with adequately stored urinary samples comparable early after transplantation. Therefore, a 5-fold cross validation was used as an internal assessment of our analytical model which resulted in a 0.81 accuracy (accuracy SD 0.11). We further assessed the logistic regression result with an additional stress-test, using a KNN model for the two selected variables and an internal cross-validation by splitting the cohort in a training (n = 50) and a prediction set (n = 25) (Supplementary Table S4 ). Either way the results of the logistic regression were well supported. Therefore, despite the lack of independent crossvalidation, we believe that this approach shows great potential in the discovery of specific and sensitive biomarkers to monitor resolution of DGF. Metabolomics studies of complex data sets, such as these constructed by urine profiling, face several challenges;
eg, multivariate models are vulnerable to noise not directly relevant to the biological question and overlap of peaks in the spectra may hinder the discovery of potential biomarkers. For example, an insignificant compound with a high concentration can mask a significant metabolite with a low concentration if both compounds have peaks with overlapping peaks in the NMR spectrum. We have attempted to overcome such issues by following a targeted approach, focusing on metabolites commonly found in human urines with emphasis on the compounds that could be more easily quantified from NMR spectra of urine samples (or other analytical platforms, eg, MS and HPLC). Both the measurements and the analysis can be performed in a high-throughput manner. Furthermore, the excellent reproducibility of NMR makes such measurements suitable for use in a daily routine procedure. In our opinion, this opens the possibility for a robust and reliable screening approach using a noninvasive, reproducible, and cost-effective method.
In conclusion, kidney transplant recipients with fDGF can be identified based on their altered urinary metabolome. Using two ratios, being lactate/fumarate and BCAAs/pyroglutamate, we could adequately predict prolonged duration of fDGF. The metabolites associated with prolonged fDGF are handled by proximal tubular epithelial cells and therefore most likely reflect tubular (dys)function.
NMR spectroscopy could therefore be a robust analytical tool to monitor resolution of fDGF and guide postoperative management.
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